CD274 and neoplasm: Target molecule expression such as PD-1 and PDL1, neo-antigens, immune gene signature, T cell clonality, tumor-infiltrating lymphocytes, and circulating lymphocytes can be estimated to monitor ICI therapy as well as to design personalized therapy regimens [148].